Wide-ranging alterations in the brain fatty acid complement of subjects with late Alzheimer’s disease as detected by GC-MS

American Journal of Translational Research

Volumn 8, Issue 1, 2016, Pages 154-165

  Nasaruddin, Muhammad Luqman ^a   Hölscher, Christian ^b   Kehoe, Patrick ^c   Graham, Stewart Francis ^d   Green, Brian Desmond ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b LANCASTER UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d Beaumont Research Institute   (United States)

Author keywords

AD; Brain tissues; DHA; Fatty acid; GC MS

Indexed keywords

DOCOSAHEXAENOIC ACID; ELAIDIC ACID; ERUCIC ACID; FATTY ACID; FATTY ACID ESTER; HEPTADECANOIC ACID; MYRISTIC ACID; PALMITIC ACID; PALMITOLEIC ACID; PENTADECANOIC ACID; STEARIC ACID;

AGED; ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; AUTOPSY; BRAIN TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; DEMENTIA; DISEASE EXACERBATION; FEMALE; HUMAN; HUMAN TISSUE; LIPID METABOLISM; MALE; MASS FRAGMENTOGRAPHY; NEUROPROTECTION; PROTEIN DENATURATION;

EID: 84957798218     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. ARUK, Dementia Statistics, http://www.alzheimersresearchuk.org/dementia-statistics/ 2014.
2. Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W and Ferri CP. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement 2013; 9: 63-75, e62.
3. Karran E, Mercken M and De Strooper B. The amyloid cascade hypothesis for Alzheimer’s disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov 2011; 10: 698-712.
4. Ittner LM and Gotz J. Amyloid-beta and tau--a toxic pas de deux in Alzheimer’s disease. Nat Rev Neurosci 2011; 12: 65-72.
5. Graham SF, Chevallier OP, Roberts D, Holscher C, Elliott CT and Green BD. Investigation of the human brain metabolome to identify potential markers for early diagnosis and therapeutic targets of Alzheimer’s disease. Anal Chem 2013; 85: 1803-1811.
6. Touboul D and Gaudin M. Lipidomics of Alzheimer’s disease. Bioanalysis 2014; 6: 541-561.
7. Cutler RG, Kelly J, Storie K, Pedersen WA, Tammara A, Hatanpaa K, Troncoso JC and Mattson MP. Involvement of oxidative stressinduced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer’s disease. Proc Natl Acad Sci U S A 2004; 101: 2070-2075.
8. Yanagisawa K, Odaka A, Suzuki N and Ihara Y. GM1 ganglioside-bound amyloid beta-protein (A beta): a possible form of preamyloid in Alzheimer’s disease. Nat Med 1995; 1: 1062-1066.
9. Berridge MJ. Inositol trisphosphate and calcium signaling. Ann N Y Acad Sci 1995; 766: 31-43.
10. Yuan Q, Zhao S, Wang F, Zhang H, Chen ZJ, Wang J, Wang Z, Du Z, Ling EA, Liu Q and Hao A. Palmitic acid increases apoptosis of neural stem cells via activating c-Jun N-terminal kinase. Stem Cell Res 2013; 10: 257-266.
11. Takenawa T and Itoh T. Phosphoinositides, key molecules for regulation of actin cytoskeletal organization and membrane traffic from the plasma membrane. Biochim Biophys Acta 2001; 1533: 190-206.
12. Wenk MR and De Camilli P. Protein-lipid interactions and phosphoinositide metabolism in membrane traffic: insights from vesicle recycling in nerve terminals. Proc Natl Acad Sci U S A 2004; 101: 8262-8269.
13. Monteiro JP, Oliveira PJ and Jurado AS. Mitochondrial membrane lipid remodeling in pathophysiology: a new target for diet and therapeutic interventions. Prog Lipid Res 2013; 52: 513-528.
14. Meikle PJ, Wong G, Barlow CK and Kingwell BA. Lipidomics: Potential role in risk prediction and therapeutic monitoring for diabetes and cardiovascular disease. Pharmacol Ther 2014; 143: 12-23.
15. Nitsch RM, Blusztajn JK, Pittas AG, Slack BE, Growdon JH and Wurtman RJ. Evidence for a membrane defect in Alzheimer disease brain. Proc Natl Acad Sci U S A 1992; 89: 1671-1675.
16. Han X, Holtzman DM and McKeel DW Jr. Plasmalogen deficiency in early Alzheimer’s disease subjects and in animal models: molecular characterization using electrospray ionization mass spectrometry. J Neurochem 2001; 77: 1168-1180.
17. Gamba P, Testa G, Sottero B, Gargiulo S, Poli G and Leonarduzzi G. The link between altered cholesterol metabolism and Alzheimer’s disease. Ann N Y Acad Sci 2012; 1259: 54-64.
18. Jones L, Holmans PA, Hamshere ML, Harold D, Moskvina V, Ivanov D, Pocklington A, Abraham R, Hollingworth P, Sims R, Gerrish A, Pahwa JS, Jones N, Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Love S, Kehoe PG, Mead S, Fox N, Rossor M, Collinge J, Maier W, Jessen F, Schurmann B, Heun R, Kolsch H, van den Bussche H, Heuser I, Peters O, Kornhuber J, Wiltfang J, Dichgans M, Frolich L, Hampel H, Hull M, Rujescu D, Goate AM, Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Al-Chalabi A, Shaw CE, Singleton AB, Guerreiro R, Muhleisen TW, Nothen MM, Moebus S, Jockel KH, Klopp N, Wichmann HE, Ruther E, Carrasquillo MM, Pankratz VS, Younkin SG, Hardy J, O’Donovan MC, Owen MJ and Williams J. Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer’s disease. PLoS One 2010; 5: e13950.
19. Sato Y, Suzuki I, Nakamura T, Bernier F, Aoshima K and Oda Y. Identification of a new plasma biomarker of Alzheimer’s disease using metabolomics technology. J Lipid Res 2012; 53: 567-576.
20. Han X, Rozen S, Boyle SH, Hellegers C, Cheng H, Burke JR, Welsh-Bohmer KA, Doraiswamy PM and Kaddurah-Daouk R. Metabolomics in early Alzheimer’s disease: identification of altered plasma sphingolipidome using shotgun lipidomics. PLoS One 2011; 6: e21643.
21. Mapstone M, Cheema AK, Fiandaca MS, Zhong X, Mhyre TR, Macarthur LH, Hall WJ, Fisher SG, Peterson DR, Haley JM, Nazar MD, Rich SA, Berlau DJ, Peltz CB, Tan MT, Kawas CH and Federoff HJ. Plasma phospholipids identify antecedent memory impairment in older adults. Nat Med 2014; 20: 415-8.
22. Wang DC, Sun CH, Liu LY, Sun XH, Jin XW, Song WL, Liu XQ and Wan XL. Serum fatty acid profiles using GC-MS and multivariate statistical analysis: potential biomarkers of Alzheimer’s disease. Neurobiol Aging 2012; 33: 1057-1066.
23. Orr SK and Bazinet RP. The emerging role of docosahexaenoic acid in neuroinflammation. Curr Opin Investig Drugs 2008; 9: 735-743.
24. Laye S. Polyunsaturated fatty acids, neuroinflammation and well being. Prostaglandins Leukot Essent Fatty Acids 2010; 82: 295-303.
25. Bazinet RP and Laye S. Polyunsaturated fatty acids and their metabolites in brain function and disease. Nat Rev Neurosci 2014; 15: 771-785.
26. Labrousse VF, Nadjar A, Joffre C, Costes L, Aubert A, Gregoire S, Bretillon L and Laye S. Short-term long chain omega3 diet protects from neuroinflammatory processes and memory impairment in aged mice. PLoS One 2012; 7: e36861.
27. Bagga D, Wang L, Farias-Eisner R, Glaspy JA and Reddy ST. Differential effects of prostaglandin derived from omega-6 and omega-3 polyunsaturated fatty acids on COX-2 expression and IL-6 secretion. Proc Natl Acad Sci U S A 2003; 100: 1751-1756.
28. Fraser T, Tayler H and Love S. Fatty acid composition of frontal, temporal and parietal neocortex in the normal human brain and in Alzheimer’s disease. Neurochem Res 2010; 35: 503-513.
29. Folch J, Lees M and Sloane Stanley GH. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 1957; 226: 497-509.
30. Cunnane SC, Schneider JA, Tangney C, Tremblay-Mercier J, Fortier M, Bennett DA and Morris MC. Plasma and brain fatty acid profiles in mild cognitive impairment and Alzheimer’s disease. J Alzheimers Dis 2012; 29: 691-697.
31. Shahar DR, Schwarzfuchs D, Fraser D, Vardi H, Thiery J, Fiedler GM, Bluher M, Stumvoll M, Stampfer MJ, Shai I and Group D. Dairy calcium intake, serum vitamin D, and successful weight loss. Am J Clin Nutr 2010; 92: 1017-1022.
32. Schmitz G and Ecker J. The opposing effects of n-3 and n-6 fatty acids. Prog Lipid Res 2008; 47: 147-155.
33. Youdim KA, Martin A and Joseph JA. Essential fatty acids and the brain: possible health implications. Int J Dev Neurosci 2000; 18: 383-399.
34. Wall R, Ross RP, Fitzgerald GF and Stanton C. Fatty acids from fish: the anti-inflammatory potential of long-chain omega-3 fatty acids. Nutr Rev 2010; 68: 280-289.
35. Bannenberg GL, Chiang N, Ariel A, Arita M, Tjonahen E, Gotlinger KH, Hong S and Serhan CN. Molecular circuits of resolution: formation and actions of resolvins and protectins. J Immunol 2005; 174: 4345-4355.
36. Schwab JM and Serhan CN. Lipoxins and new lipid mediators in the resolution of inflammation. Curr Opin Pharmacol 2006; 6: 414-420.
37. Serhan CN, Hong S, Gronert K, Colgan SP, Devchand PR, Mirick G and Moussignac RL. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med 2002; 196: 1025-1037.
38. Patterson E, Wall R, Fitzgerald GF, Ross RP and Stanton C. Health implications of high dietary omega-6 polyunsaturated Fatty acids. J Nutr Metab 2012; 2012: 539426.
39. Cagnin A, Brooks DJ, Kennedy AM, Gunn RN, Myers R, Turkheimer FE, Jones T and Banati RB. In-vivo measurement of activated microglia in dementia. Lancet 2001; 358: 461-467.
40. Griffin WS, Stanley LC, Ling C, White L, MacLeod V, Perrot LJ, White CL 3rd and Araoz C. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci U S A 1989; 86: 7611-7615.
41. Sanchez-Mejia RO and Mucke L. Phospholipase A2 and arachidonic acid in Alzheimer’s disease. Biochim Biophys Acta 2010; 1801: 784-790.
42. Serhan CN, Arita M, Hong S and Gotlinger K. Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their endogenous aspirin-triggered epimers. Lipids 2004; 39: 1125-1132.
43. Henry GE, Momin RA, Nair MG and Dewitt DL. Antioxidant and cyclooxygenase activities of fatty acids found in food. J Agric Food Chem 2002; 50: 2231-2234.
44. Astarita G, Jung KM, Vasilevko V, Dipatrizio NV, Martin SK, Cribbs DH, Head E, Cotman CW and Piomelli D. Elevated stearoyl-CoA desaturase in brains of patients with Alzheimer’s disease. PLoS One 2011; 6: e24777.
45. Zhao Y, Calon F, Julien C, Winkler JW, Petasis NA, Lukiw WJ and Bazan NG. Docosahexaenoic acid-derived neuroprotectin D1 induces neuronal survival via secretase-and PPARgammamediated mechanisms in Alzheimer’s disease models. PLoS One 2011; 6: e15816.
46. Lukiw WJ, Cui JG, Marcheselli VL, Bodker M, Botkjaer A, Gotlinger K, Serhan CN and Bazan NG. A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J Clin Invest 2005; 115: 2774-2783.
47. Hong S, Gronert K, Devchand PR, Moussignac RL and Serhan CN. Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation. J Biol Chem 2003; 278: 14677-14687.
48. Lee JT, Xu J, Lee JM, Ku G, Han X, Yang DI, Chen S and Hsu CY. Amyloid-beta peptide induces oligodendrocyte death by activating the neutral sphingomyelinase-ceramide pathway. J Cell Biol 2004; 164: 123-131.
49. Roher AE, Weiss N, Kokjohn TA, Kuo YM, Kalback W, Anthony J, Watson D, Luehrs DC, Sue L, Walker D, Emmerling M, Goux W and Beach T. Increased A beta peptides and reduced cholesterol and myelin proteins characterize white matter degeneration in Alzheimer’s disease. Biochemistry 2002; 41: 11080-11090.
50. Patil S and Chan C. Palmitic and stearic fatty acids induce Alzheimer-like hyperphosphorylation of tau in primary rat cortical neurons. Neurosci Lett 2005; 384: 288-293.
51. Grimm MO, Rothhaar TL, Grosgen S, Burg VK, Hundsdorfer B, Haupenthal VJ, Friess P, Kins S, Grimm HS and Hartmann T. Trans fatty acids enhance amyloidogenic processing of the Alzheimer amyloid precursor protein (APP). J Nutr Biochem 2012; 23: 1214-1223.